Merck, 341607-5MG, FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074

General description
A cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors (IC₅₀ = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src only at much higher concentration (IC₅₀ = 17.6 µM, 19.8 µM, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µM. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC₅₀in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Koziczak, M., et al. 2004. Oncogene23, 3501.
Trudel, S., et al. 2004. Blood103, 3521.
Skaper, S.D., et al. 2000. J. Neurochem.75, 1520.
Mohammadi, M., et al. 1998. EMBO J.17, 5896.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Irritant (B)